

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 6, 2006

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida 000-50614 59-3410522

(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

13200 Progress Boulevard
Alachua, Florida 32615

(Address of principal executive offices including zip code)

(386) 418-4018

Registrant's telephone number, including area code

None

(Former name or former address, if changed since last report.)

Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On January 6, 2006, Oragenics, Inc. ("the Company") entered into a Securities Purchase Agreement with a group of private accredited investors providing for the issuance of up to 1,500,000 shares of Company common stock at \$0.40 per share and 1,500,000 warrants to purchase common stock at an exercise price of \$0.60 per share. The warrants will be exercisable for two years and are callable by the Company if its common stock trades at or above \$1.60 per share for a 30 consecutive day period. Also, pursuant to the terms of a Registration Rights Agreement dated January 6, 2006, the Company will be obligated to file a registration statement with the Securities and Exchange Commission covering the resale of shares of common stock purchased the private investors and the shares of common stock issuable upon exercise of the warrants. The private placement offering is being made pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933 and closing is expected to occur on or before February 8, 2006. A copy of the January 11, 2006 press release announcing the financing agreement is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 5.02 ELECTION OF DIRECTORS

At the meeting of the Board of Directors on January 6, 2006, Oragenics' Board of Directors re-elected Dr. Robert Zahradnik as a Director of the Company. Dr. Zahradnik had resigned his Board position earlier in 2005 so as to comply with the American Stock Exchange's small business required ratio of at least 50% of the board being independent board members. Dr. Zahradnik also currently serves as the Company's President and Chief Executive Officer.

Item 8.01 OTHER EVENTS

On December 19, 2005, Oragenics, Inc. ("the Company") entered into a consulting arrangement with Dr. Raman Bedi, the former Chief Dental Officer for England. Dr. Bedi will organize and chair the Company's International Advisory Committee that will include world leading experts in oral health care. A copy of the January 10, 2006 press release announcing the hiring of Dr. Raman Bedi is attached to this report as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.

Number	Description
99.1	Press Release dated January 11, 2006
99.2	Press Release dated January 10, 2006

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 12th day of January, 2006.

ORAGENICS, INC.
(Registrant)

BY: /s/ Robert T. Zahradnik

Robert T. Zahradnik
President and Chief Executive Officer

FOR IMMEDIATE RELEASE

Dr. Raman Bedi joins Oragenics as Senior Consultant

ALACHUA, FL (January 10, 2006) - Oragenics, Inc. (AMEX: ONI) today announced that Dr. Raman Bedi has joined the Company as senior consultant. In addition, he has agreed to organize and chair its International Advisory Committee of world leading experts in oral health care. Dr. Bedi became the 8th Chief Dental Officer for England in 2002, following a distinguished academic career and having been awarded the Foundation chair in Transcultural Oral Health at University College London (1996-2002). Dr. Bedi retired from the post of Chief Dental Officer in October 2005 and is returning to his chair at Kings College London. He has published over 185 scientific papers and authored four books.

"Oragenics is honored to have someone of Dr. Bedi's stature agree to chair our Advisory Committee," said Dr. Zahradnik, Oragenics' Chief Executive Officer. "As senior consultant, Professor Bedi, will spearhead a global strategy for moving our technologies through clinical trials, partnering and commercialization."

Dr. Bedi is the past President of the British Society for Disability and Oral Health (2002), Past President of the Education Research Group of the International Association for Dental Research (IADR)(2002-2004) and past chair of the IADR Regional Development Program Committee (2002-2004). He was a member of the NHS Top team (2002-2005) and Founder member of the National Health and Social care leadership network (2004-2005). In Higher Education, he is a Board member of the Higher Education Funding Council strategic committee on wider participation and Board member of the HE Leadership Foundation.

"These are exciting and challenging times for dentistry," stated Dr. Bedi, "and I look forward to working with Oragenics. They are an intriguing company with a portfolio of unique products, including their breakthrough technology, replacement therapy. I am ready to begin organizing and chairing the International Advisory Committee on how best new technologies can address and eradicate the commonest disease in children, namely dental caries. Oragenics has the potential to become a global player in the promotion of oral health."

About Oragenics

Oragenics, Inc. is an emerging biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. The company's lead product is a novel oral vaccine for the prevention of tooth decay. The company is also developing a novel antibiotic with broad-spectrum activity against gram-positive bacteria and a probiotic product aimed at maintaining oral health. The company is headquartered in Alachua, Florida. For more information about Oragenics, please consult the company's website at www.oragenics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (1) the ability to successfully complete development and commercialization of Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic, and probiotic product for oral health; (2) the ability to obtain substantial additional funding; (3) the ability to develop and commercialize products before competitors; (4) the ability to develop commercial products with the in-licensed technology; and (5) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Exhibit 99.2

FOR IMMEDIATE RELEASE

Oragenics Announces Financing Commitment of \$600,000

ALACHUA, FL (January 11, 2006): Oragenics, Inc. (AMEX:ONI) announced today that it has entered into a definitive agreement for equity based financing of up to \$600,000 from a group of accredited investors that include board members and executive management of the Company. The agreement provides for the sale of up to 1,500,000 newly issued shares of common stock at a price of \$0.40 per share and the issuance of an equal number of warrants to purchase shares of common stock that will be exercisable at \$0.60 per share. The transaction is expected to close by February 8, 2006.

Last month the Company closed on a round of financing totaling \$1.175 million on terms similar to the investment currently being announced. As stated by Oragenics' President and CEO, Dr. Robert Zahradnik, "This financing allows the Company to continue to advance clinical and preclinical work on our lead programs. I believe this added investment reflects growing confidence by investors in the underlying technology of the Company."

Neither the shares of common stock, nor the shares of common stock underlying the warrants are registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. However, the company will be obligated to file a resale registration statement with the Securities and Exchange Commission relating to the shares of common stock to be issued in the transaction and the shares of common stock to be issued upon exercise of the warrants within forty five days of the closing. Oragenics plans to use the funds raised to support the clinical development of the company's various technologies and for general corporate purposes.

In an unrelated event, Oragenics' Board of Directors re-elected Dr. Robert Zahradnik as a Director of the Company on January 6, 2006. Dr. Zahradnik had resigned his Board position earlier in 2005 so as to comply with the American Stock Exchange's small business required ratio of at least 50% of the board being independent board members. As a result of Dr. Zahradnik's re-election, the Board will now consist of three independent members and two Company executives including Dr. Zahradnik.

About Oragenics

Oragenics is focused on the development of novel technologies and products to address significant, unmet medical needs. Oragenics' strategy is to license and develop products through human proof-of-concept studies prior to partnering with major pharmaceutical, biotechnology or healthcare product firms for advanced clinical development and commercialization. Upon completion of the private placement financing Oragenics plans to continue its development of the following products, which address potentially major market opportunities:

- o SMaRT Replacement Therapy is a single, painless topical treatment that has the potential to offer life-long protection from most tooth decay.
- o MU 1140 is a novel antibiotic with activity against many Gram-positive bacteria including multidrug resistant *Staphylococcus aureus* and *Enterococcus faecalis*. MU 1140 has a number of other characteristics that suggest its potential use in the treatment of a variety of infectious diseases.
- o Probiora 3 Oral Probiotic Treatment employs naturally occurring beneficial bacteria to promote oral and periodontal health. Such products may be marketed without the need for extensive regulatory filings in certain markets. Oragenics plans to conduct a human study in early 2006 to support the commercialization of Probiora 3. For more information about Oragenics, please consult the company's website at www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics'

current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to successfully close on the above described private placement, those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.